Nathalie Imbault
Overview
Explore the profile of Nathalie Imbault including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
211
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Choi E, Kasonia K, Kavunga-Membo H, Mukadi-Bamuleka D, Soumah A, Mossoko Z, et al.
Vaccines (Basel)
. 2024 Aug;
12(8).
PMID: 39203955
During the 2018-2020 Ebola virus disease outbreak in Democratic Republic of the Congo, a phase 3 trial of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine (DRC-EB-001) commenced in Goma, with participants being...
2.
Kavunga-Membo H, Watson-Jones D, Kasonia K, Edwards T, Camacho A, Mambula G, et al.
Vaccines (Basel)
. 2024 Aug;
12(8).
PMID: 39203952
During the 2018-2020 Ebola virus disease (EVD) outbreak, residents in Goma, Democratic Republic of the Congo, were offered a two-dose prophylactic EVD vaccine. This was the first study to evaluate...
3.
Salami K, Mandi H, Imbault N, Tornieporth N
Pan Afr Med J
. 2022 Jun;
41:242.
PMID: 35734313
Introduction: Lassa fever runs a uniquely severe course in pregnancy. There are plans for Lassa fever vaccine clinical trials in endemic West African countries. We assessed the perception of West...
4.
Salami K, Imbault N, Erlebach A, Urban J, Zoglowek M, Tornieporth N
Pilot Feasibility Stud
. 2020 Feb;
6:24.
PMID: 32082610
Background: We sought to develop and test an objective scorecard-based system for assessing and categorizing available research sites in Lassa fever-affected countries based on their preparedness and capability to host...
5.
Chitnis C, Mukherjee P, Mehta S, Yazdani S, Dhawan S, Shakri A, et al.
PLoS One
. 2015 Sep;
10(9):e0137816.
PMID: 26332825
[This corrects the article DOI: 10.1371/journal.pone.0117820.].
6.
Chitnis C, Mukherjee P, Mehta S, Yazdani S, Dhawan S, Shakri A, et al.
PLoS One
. 2015 May;
10(4):e0117820.
PMID: 25927360
Background: A phase I randomised, controlled, single blind, dose escalation trial was conducted to evaluate safety and immunogenicity of JAIVAC-1, a recombinant blood stage vaccine candidate against Plasmodium falciparum malaria,...
7.
Leroy O, Geels M, Korejwo J, Dodet B, Imbault N, Jungbluth S
Vaccine
. 2014 Aug;
32(51):7021-7024.
PMID: 25148773
To consolidate the integration of the fragmented European vaccine development landscape, TRANSVAC - the European Network of Vaccine Research and Development, funded by the European Commission (EC) - has initiated...
8.
Geels M, Imoukhuede E, Imbault N, van Schooten H, McWade T, Troye-Blomberg M, et al.
Expert Rev Vaccines
. 2011 Nov;
10(12):1697-708.
PMID: 22085173
For over 10 years, the European Vaccine Initiative (EVI; European Malaria Vaccine Initiative until 2009) has contributed to the development of 24 malaria candidate vaccine antigens with 13 vaccine candidates...
9.
Belard S, Issifou S, Hounkpatin A, Schaumburg F, Ngoa U, Esen M, et al.
PLoS One
. 2011 Aug;
6(7):e22525.
PMID: 21829466
Background: GMZ2 is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP) that mediates an immune response against the blood stage of the...
10.
Mordmuller B, Szywon K, Greutelaers B, Esen M, Mewono L, Treut C, et al.
Vaccine
. 2010 Aug;
28(41):6698-703.
PMID: 20696154
Malaria is still one of the major public health threats in sub-Saharan Africa. An effective vaccine could be a sustainable control measure that can be integrated into existing health infrastructures....